Short-Term Safety and Efficacy of Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

Abstract

Off-label intravitreal bevacizumab therapy for neovascular ARMD was well tolerated over 3 months with improvements in visual acuity and OCT central retinal thickness measurements. While the long-term safety and efficacy of intravitreal bevacizumab remain unknown, these short-term results suggest that intravitreal bevacizumab may be the most cost effective therapy for the treatment of neovascular ARMD.

Reversible myocardial dysfunction following intraocular bevacizumab administration

“…4 On the other hand, intraocular injection of low-dose bevacizumab is considered as a safe and effective treatment for neovascular age-related macular degeneration. 5,6 Observational studies have reported no significant short-term side effects and few long-term cardiovascular side effects. 6e8 To our knowledge, there have been no reports of acute cardiac complications with bevacizumab treatment.…”

Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration

“…[12][13][14] In contrast, some cases of retinal pigment epithelial (RPE) tears after bevacizumab therapy have recently been reported. [15][16][17][18][19][20][21][22][23][24][25][26] Since intravitreal bevacizumab is a widely used therapy option for neovascular AMD, there is a need for further information on this topic.…”

Bevacizumab: a new hope?

“…8 Within 12 months, bevacizumab use had become international and several reports on its efficacy and safety were published. [9][10][11][12][13] In this edition of EYE, Cleary et al 14 contribute to the literature, reporting on the effect of intravitreal bevacizumab on occult and classic CNV in 112 eyes. Overall vision improved from 0.84 Log MAR (6/41) at baseline to 0.69 Log MAR (6/30) at 9 months after an average of 1.69 injections.…”